DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scoring in Patients With Femoropopliteal Arterial Disease
- Sponsor
- Marc Sirvent
- Study ID
- NCT07764016
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Critical Limb-Threatening Ischaemia
- Drug Coated Balloon
- Femoropopliteal Disease
- Peripheral Arterial Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Non-compliant Plain Balloon angioplasty (PBA) — DEVICEThe intervention consists of preparing the artery with a non-compliant plain balloon before using the DCB (Legflow XP™; Manufacturer: Cardionovum GmbH Bonn, Germany).
- Non-compliant Scoring Balloon Angioplasty (SB) — DEVICEThe intervention consists of preparing the artery with a non-compliant scoring balloon (DKutting™; Manufacturer: DK Medical Technology Co., Ltd., Suzhou, China) before using the DCB (Legflow XP™; Manufacturer: Cardionovum GmbH Bonn, Germany) as definitve treatment.
Study Details
The aim of this clinical trial is to determine whether vessel preparation with a non-compliant scoring balloon before drug-coated balloon (DCB) angioplasty provides superior procedural and clinical outcomes compared with vessel preparation using a non-compliant plain balloon in patients with chronic limb-threatening ischaemia (CLTI) undergoing femoropopliteal endovascular intervention. The main questions the study aims to answer are: * Does non-compliant scoring balloon vessel preparation reduce the need for bailout stenting during the index procedure? * Does it improve primary patency after DCB angioplasty? * Does it improve clinically relevant outcomes such as wound healing, freedom from clinically driven target lesion revascularisation, limb salvage and health-related quality of life? * Does it provide procedural and economic advantages compared with non-compliant plain balloon vessel preparation? Participants will be randomly assigned to undergo vessel preparation using either a non-compliant plain balloon or the DKutting™ non-compliant scoring balloon, followed by angioplasty with the Legflow XP™ drug-coated balloon. Patients will undergo clinical, duplex ultrasound and quality-of-life follow-up for 24 months.
Key Dates
- First listed
- Aug 13, 2026
- Start date
- Dec 31, 2026
- Status verified
- Aug 2026
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 142 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Non-compliant plain balloon (PBA)* Vessel preparation using non-compliant plain balloon * Definitive treatment: drug-coated balloon angioplasty (Legflow XP™; Manufacturer: Cardionovum GmbH Bonn, Germany).
- Active Comparator: Scoring balloon (SB)* Vessel preparation using non-compliant scoring balloon (DKutting™; Manufacturer: DK Medical Technology Co., Ltd., Suzhou, China) * Definitive treatment: drug-coated balloon angioplasty (Legflow XP™; Manufacturer: Cardionovum GmbH Bonn, Germany) as definitve treatment.
Primary Outcome Measure
Bailout stenting [ Time Frame: At index procedure ]
Central Contacts
- Marc Sirvent, PhD+34938425000
Related Studies
- FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial DiseasePHASE1/PHASE2 · Not Yet Recruiting · Venturis Therapeutics, Inc. · Chicago, Illinois
- Multi-Center Registry for Peripheral Arterial Disease Interventions and OutcomesRecruiting · Baylor Research Institute · Detroit, Michigan
- A Real-World Registry of Chronic Wounds and UlcersRecruiting · U.S. Wound Registry · The Woodlands, Texas
- Ramipril Treatment of Claudication: Oxidative Damage and Muscle FibrosisPHASE4 · Recruiting · University of Nebraska · Omaha, Nebraska